



---

## Indiana University Health Ball Memorial Department of Research Open Clinical Trials.

**AEGIS II****PI: Bruce Graham, MD****Coordinator – Erin Loomis**

Phase 3 trial of infusing intravenous apolipoprotein A-1(CSL112) to find out how effective this drug is in reducing the risk of heart related events in patients that have been diagnosed with Acute Coronary Syndrome (ACS). Open for enrollment.

**AIRWISE****PI: Rajeev Mehta, MD, FCCP****Coordinator – Sherry Adair/Chris Yencer**

Randomized Clinical Trial in a Community-Based setting comparing STIOLTO<sup>®</sup> RESPIMAT<sup>®</sup> vs. ICS-LABA plus LAMA (Triple Therapy) in Patients with COPD. Open for enrollment.

**AKEBIA PRO<sub>2</sub>TECT****PI: Unnikrishna Pillai, MD****Coordinator - Erin Loomis**

Phase 3 randomized, open-label, active-controlled clinical study evaluating the effect of treatment and safety of Vadadustat (study drug). This drug is used for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease. Open for enrollment.

**ANTHEM HFrEF****PI: Bruce Graham MD****Coordinator – Ali Belangee**

Device-Based therapy called Autonomic Regulation Therapy (ART) to treat patients with chronic heart failure. Open for enrollment.

**APPRAISE-ATP****PI: Bruce Graham, MD****Coordinator – Sherry Adair**

The purpose of this study is to determine which programming arm, antitachycardic pacing followed by defibrillation or defibrillation only, is the best option (works the best and is the safest) for this patient population. Open for enrollment.

**CONNECT HF****PI: Wayne Gray, MD****Coordinator – Sherry Adair**

This study is a hospital-based quality improvement (QI) trial, comparing two QI processes in heart failure patients. Open for enrollment.

**GALACTIC****PI: Wayne Gray, MD****Coordinator – Erin Loomis**

The purpose of this study is to evaluate whether treatment with omecamtiv mecarbil (study drug) compared to placebo, in subjects with chronic heart failure with reduced ejection fraction, improves heart function in patients receiving standard therapy. Open for enrollment.

**HEART-FID/FIRE-HF****PI: Wayne Gray, MD****Coordinator – Sherry Adair/Ali Belangee**

Purpose for this study is to determine the safety and effect of treatment of iron therapy in patients with heart failure and anemia. Open for enrollment.

**INDIANA BIOBANK****PI: Brandon Dickey, MD****Coordinator – Mona Geinosky**

The purpose of this research study is to obtain a blood sample and personal health information located in one place (bank) to conduct research on many diseases and health conditions that affect Hoosiers. Open for enrollment.

**PARADISE****PI: Bruce Graham, MD****Coordinator – Ali Belangee**

The purpose of this study is to test if LCZ696 (study drug) taken twice a day compared to Ramipril taken twice a day, is safe and effective in decreasing complications following an acute myocardial infarction (heart attack). Open for enrollment.

**SOLOIST****PI: Bruce Graham, MD****Coordinator – Sherry Adair**

This study is being done to evaluate if the study drug, Sotagliflozin, is safe for those patients that have been diagnosed with heart failure and type 2 diabetes. Open for enrollment.

**BSC-SMART Registry****PI: Michael Moran, MD, FACC****Coordinator – Sherry Adair**

The study is being done for patients who have Cardiac Resynchronization Therapy Defibrillators (CRT-D), to learn which optimization techniques are used and how effective they are. Open for enrollment.